Tag: hemophilia
Novo Nordisk: ‘very encouraging’ data in hemophilia A
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Sanofi announces new data on its hemophilia treatments
Published on 06/21/2024 at 07:01 a.m. June 21 (Reuters) – Sanofi SA: * NEW DATA ON ALTUVIIIO AND FITUSIRAN STRENGTHEN SANOFI’S LEADERSHIP…
Sanofi: New data on ALTUVIIIO and fitusiran reinforce Sanofi’s leadership in the treatment of hemophilia
By Claude Leguilloux Published on 06/21/2024 at 7:23 a.m. Photo credit © Sanofi Corporate (Boursier.com) — The…
Novo Nordisk: Result of a study for hemophilia A
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Novo Nordisk: positive trial in hemophilia care
(CercleFinance.com) – Novo Nordisk today announced topline results from a pivotal phase 3a trial investigating the efficacy and safety of Mim8 compared to no prophylaxis and compared to prior prophylactic…
Sanofi: Marketing Authorization in hemophilia A in Japan – 09/25/2023 at 09:33
(CercleFinance.com) – Sanofi announces that the Japanese Ministry of Health has issued a marketing authorization (MA) for Altuviiio once a week, for the control of bleeding in patients with hemophilia…
Sanofi: positive data in hemophilia A in children – 06/26/2023 at 09:17
(CercleFinance.com) – Sanofi announces positive data from the pivotal phase III XTEND-Kids study which evaluated ALTUVIIIO, at a weekly prophylactic dose, in patients under 12 years of age with hemophilia…
Sanofi: positive data in hemophilia A in children
(CercleFinance.com) – Sanofi announces positive data from the pivotal phase III XTEND-Kids study which evaluated ALTUVIIIO, at a weekly prophylactic dose, in patients under 12 years of age with hemophilia…
Sanofi presents positive results against hemophilia – 06/26/2023 at 10:35
(AOF) – Sanofi (-0.53% to 98.08 euros) announces positive results against hemophilia. Data from pivotal XTEND-Kids study, which evaluated Altuviiio in treatment-experienced patients under 12 years of age with severe…
Sanofi: encouraging data in hemophilia A in children under 12
By Alexandra Saintpierre Published on 06/25/2023 at 6:52 p.m. Photo credit © Sanofi (Boursier.com) — Data from the…
Sanofi: FDA grants priority review to treatment for hemophilia A
Agefi – Dow Jones | On 08/30/22 at 07:53 Sanofi: FDA grants priority review to treatment for hemophilia A | Photo credits: Sanofi Pasteur/Vincent Moncorgé PARIS (Agefi-Dow Jones)–The pharmaceutical company…
Sanofi: positive phase III data in hemophilia A – 07/11/2022 at 07:25
(CercleFinance.com) – Sanofi announces positive results from the pivotal phase III XTEND-1 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alpha in adults and adolescents aged 12 or over…